Assyro AI

FDA Orange Book · active-ingredient family

Zonisamide

Zonisamide is approved as 2 brand and 19 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:ZONISADE · NDA 214273

2

Brand (NDA)

19

Generics (ANDA)

3

Listed patents

0

Exclusivity periods

Brand (NDA) products · capsule, suspension

ProductApplicantApplicationTEApproved
ZONISADERLDAZURITYNDA 214273Jul 15, 2022
ZONEGRANRLD×3ADVANZ PHARMANDA 020789ABAug 22, 2003

Generic (ANDA) products (19)

ProductApplicantApplicationTEApproved
ZONISAMIDE×3MACLEODS PHARMS LTDANDA 219507May 12, 2025
ZONISAMIDE×3UNICHEMANDA 214492ABJan 26, 2021
ZONISAMIDE×3EPIC PHARMA LLCANDA 077876Feb 21, 2007
ZONISAMIDE×3ZYDUS LIFESCIENCESANDA 077625ABOct 16, 2006
ZONISAMIDE×3AUROBINDO PHARMA LTDANDA 077645ABSep 29, 2006
ZONISAMIDE×3BIONPHARMAANDA 077813ABAug 16, 2006
ZONISAMIDE×3GRANULESANDA 077636ABJul 27, 2006
ZONISAMIDE×3INVAGEN PHARMSANDA 077869ABMay 31, 2006
ZONISAMIDE×3CHARTWELL RXANDA 077650Apr 20, 2006
ZONISAMIDE×3SUN PHARM INDS (IN)ANDA 077634Mar 17, 2006
ZONISAMIDE×3GLENMARK PHARMSANDA 077651ABJan 30, 2006
ZONISAMIDE×3ANI PHARMSANDA 077639Dec 22, 2005
ZONISAMIDE×3ANI PHARMSANDA 077641Dec 22, 2005
ZONISAMIDE×3APOTEXANDA 077642Dec 22, 2005
ZONISAMIDE×3PHARMOBEDIENTANDA 077647Dec 22, 2005
ZONISAMIDE×3RISINGANDA 077637Dec 22, 2005
ZONISAMIDE×3ROXANEANDA 077648Dec 22, 2005
ZONISAMIDE×3SUN PHARM INDUSTRIESANDA 077635Dec 22, 2005
ZONISAMIDE×3UPSHER SMITH LABSANDA 077644Dec 22, 2005

Listed patents (3)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
11478456Aug 18, 2038in 12 yr 4 mo
U-3458
12491179Aug 18, 2038in 12 yr 4 mo
Product
11529333Aug 18, 2038in 12 yr 4 mo
Product

Zonisamide — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.